ALK and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) patients who harbor chromosomal rearrangements of the anaplastic lymphoma kinase (ALK) gene are highly sensitive to small-molecule ALK tyrosine kinase inhibitors (TKIs) [1–3].